Nom du produit:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

CAS:17412-23-6
Formule moléculaire:C8H8ClN3
Pureté:95%+
Numéro de catalogue:CM330120
Poids moléculaire:181.62

Unité d'emballage Stock disponible Prix($) Quantité
CM330120-50mg in stock ƩƩ
CM330120-100mg in stock ǕŔƏ
CM330120-250mg in stock Ǖƻș
CM330120-1g in stock șŔŭ
CM330120-5g in stock ƅŭŭ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:17412-23-6
Formule moléculaire:C8H8ClN3
Point de fusion:-
Code SMILES:CC1=CC(Cl)=NN2C1=NC(C)=C2
Densité:
Numéro de catalogue:CM330120
Poids moléculaire:181.62
Point d'ébullition:
N° Mdl:MFCD27946129
Stockage:

Category Infos

Imidazopyridazines
Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.